Jun 11, 2020 / 02:30PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good morning, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Karuna Therapeutics here with us. So we do have Steve Paul, Chairman and CEO; Troy Ignelzi, Chief Financial Officer; and Andrew Miller, Chief Operating Officer.
So with that, a question for the team here, you're a best-performing IPO last year and saw -- on the back of success with your portfolio, can you start by giving us a brief overview of Karuna and how the company's approach in your psychiatric disorders is differentiated from others?
Questions and Answers:
Steven M. Paul - Karuna Therapeutics, Inc. - CEO, President & ChairmanAbsolutely. First off, Salveen, thank you so much for inviting us to the conference and for emceeing this fireside chat. Really appreciate it.
Karuna is developing what we hope will be a best-in-class medicine for treating psychosis broadly defined. And what I think has differentiated us, we're not
Trustpilot
